What is Hadlima Pushtouch?
Hadlima Pushtouch is the brand name for an injectable medication containing adalimumab-bwwd, a biosimilar of the reference product Humira (adalimumab). A biosimilar is a biologic product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. The 'Pushtouch' refers to the specific delivery system: a single-use, prefilled autoinjector designed for patient convenience and ease of use. The medication works as a tumor necrosis factor (TNF) blocker, targeting a protein in the body that causes inflammation in various autoimmune diseases. By blocking TNF, adalimumab can significantly reduce signs and symptoms, inhibit disease progression, and improve physical function.
Indications for Hadlima Pushtouch
Hadlima is a versatile biologic treatment approved for a broad range of inflammatory conditions in both adults and pediatric patients. A healthcare provider determines the appropriate dosage and treatment regimen based on the patient's specific condition and response to therapy.
In adults, Hadlima Pushtouch is used to treat:
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
- Ankylosing Spondylitis (AS)
- Crohn's Disease (CD)
- Ulcerative Colitis (UC)
- Plaque Psoriasis (Ps)
- Hidradenitis Suppurativa (HS)
- Uveitis
In pediatric patients, Hadlima is indicated for:
- Juvenile Idiopathic Arthritis (JIA) in patients aged 2 and older
- Crohn's Disease in patients aged 6 and older
The Ease of the PushTouch Autoinjector
The PushTouch delivery system is designed for patient convenience and has received recognition for its ease of use.
Key features of the PushTouch autoinjector include:
- Buttonless operation; injection starts when pressed firmly against the skin.
- Audible clicks to indicate the start and completion of the injection.
- Ergonomic design for a secure grip.
- Thin 29-gauge needle.
- Large window to view medication.
Administering and Storing Hadlima Pushtouch
Proper administration and storage are crucial for efficacy. Patients should receive training from a healthcare professional.
Administration instructions:
- Wash hands and select an injection site on the thigh or abdomen, avoiding the navel area. Rotate sites with each dose.
- Clean the site with an alcohol swab and let it dry.
- Remove the cap and press the autoinjector firmly against the skin until the first click. Hold until the second click confirms the dose is delivered.
- Dispose of the used autoinjector in a sharps container.
Storage requirements:
- Refrigerate between 36°F and 46°F (2°C to 8°C).
- Do not freeze and protect from light.
- Can be stored at room temperature (up to 77°F) for up to 14 days for travel; discard if not used within this time.
Important Safety Considerations
Screening for infections like TB is necessary before starting Hadlima, as TNF blockers can increase infection risk.
Potential serious risks include:
- Serious Infections (including TB)
- Malignancies (lymphoma and other cancers)
- Hepatitis B Reactivation
- Heart Failure (new or worsening)
- Neurologic Reactions
Discuss your medical history with your doctor. Avoid live vaccines while on Hadlima.
Conclusion
What is the use of Hadlima Pushtouch? It is an important biosimilar treatment for numerous chronic inflammatory and autoimmune conditions, offering an alternative to Humira. The Pushtouch autoinjector enhances the self-administration process. By blocking TNF, Hadlima helps manage symptoms and improve quality of life. Following medical guidance and monitoring for side effects are crucial.
Hadlima vs. Humira: Key Differences
| Feature | Hadlima (adalimumab-bwwd) | Humira (adalimumab) |
|---|---|---|
| Classification | Biosimilar (interchangeable in some regions) | Reference biologic |
| Formulation | Low and high-concentration options available in Pushtouch autoinjector, prefilled syringe, and vial | Multiple formulations available, including autoinjector |
| Autoinjector Mechanism | Buttonless, with audible start-stop clicks | Push-button injection |
| Cost | Generally more affordable due to biosimilar pricing | Historically expensive, though costs vary based on insurance |
| Efficacy & Safety | No clinically meaningful difference in safety or effectiveness | Established efficacy and safety profile through decades of use |
| Indications | Approved for a wide range of autoimmune and inflammatory conditions | Approved for a similar range of inflammatory conditions |
| Interchangeability | Designated interchangeable, allowing for pharmacist substitution in some areas | Not interchangeable with biosimilars; is the reference product |
